PL3268356T3 - Związki heterocykliczne i sposoby ich stosowania - Google Patents

Związki heterocykliczne i sposoby ich stosowania

Info

Publication number
PL3268356T3
PL3268356T3 PL16715616T PL16715616T PL3268356T3 PL 3268356 T3 PL3268356 T3 PL 3268356T3 PL 16715616 T PL16715616 T PL 16715616T PL 16715616 T PL16715616 T PL 16715616T PL 3268356 T3 PL3268356 T3 PL 3268356T3
Authority
PL
Poland
Prior art keywords
methods
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
PL16715616T
Other languages
English (en)
Inventor
Jane Brown
Alan Naylor
John Paul Watts
Thomas David Mccarthy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015900878A external-priority patent/AU2015900878A0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3268356T3 publication Critical patent/PL3268356T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL16715616T 2015-03-12 2016-03-09 Związki heterocykliczne i sposoby ich stosowania PL3268356T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2015900878A AU2015900878A0 (en) 2015-03-12 Heterocyclic compounds and methods for their use
AU2015902830A AU2015902830A0 (en) 2015-07-17 Heterocyclic compounds and methods for their use
PCT/IB2016/051318 WO2016142867A1 (en) 2015-03-12 2016-03-09 Heterocyclic compounds and methods for their use
EP16715616.5A EP3268356B1 (en) 2015-03-12 2016-03-09 Heterocyclic compounds and methods for their use

Publications (1)

Publication Number Publication Date
PL3268356T3 true PL3268356T3 (pl) 2022-01-24

Family

ID=60544648

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16715616T PL3268356T3 (pl) 2015-03-12 2016-03-09 Związki heterocykliczne i sposoby ich stosowania

Country Status (8)

Country Link
US (1) US10308628B2 (pl)
EP (1) EP3268356B1 (pl)
JP (1) JP6826993B2 (pl)
CN (1) CN107466293B (pl)
ES (1) ES2898635T3 (pl)
PL (1) PL3268356T3 (pl)
PT (1) PT3268356T (pl)
WO (1) WO2016142867A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンii2型拮抗薬としてのピロリジン誘導体
PT3510033T (pt) 2016-09-09 2022-02-18 Novartis Ag Compostos e composições como inibidores de recetores endossomais do tipo toll

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
EP2650010A1 (en) 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
JP5230595B2 (ja) 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
CN102821765A (zh) 2010-01-19 2012-12-12 西芬克斯医药有限公司 改良神经传导速度的方法和组合物
PL2595960T3 (pl) 2010-07-21 2016-09-30 Sól i solwaty pochodnej tetrahydroizochinoliny
CA2860577C (en) 2012-01-06 2020-09-15 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds as angiotensin ii type 2 receptor antagonists
CA2861231C (en) 2012-01-25 2021-04-13 Spinifex Pharmaceuticals Pty Ltd Substituted 1-acyl-piperazine and 1-acyl-perhydro-1,4-diazepine compounds and their use as angiotensin ii type 2 receptor antagonists
WO2013110135A1 (en) * 2012-01-25 2013-08-01 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
EP3019477B1 (en) * 2013-07-08 2021-05-26 Novartis AG Heterocyclic compounds and methods of their use
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンii2型拮抗薬としてのピロリジン誘導体

Also Published As

Publication number Publication date
EP3268356A1 (en) 2018-01-17
US20180057477A1 (en) 2018-03-01
JP6826993B2 (ja) 2021-02-10
PT3268356T (pt) 2021-11-23
US10308628B2 (en) 2019-06-04
ES2898635T3 (es) 2022-03-08
EP3268356B1 (en) 2021-08-25
CN107466293A (zh) 2017-12-12
WO2016142867A1 (en) 2016-09-15
JP2018507897A (ja) 2018-03-22
CN107466293B (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
HK1255102A1 (zh) 雜環化合物及其應用
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
HK1223100A1 (zh) 雜環化合物
RS65411B1 (sr) Jedinjenja neuroatenuirajućeg norketamina i metodi
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
IL247018A0 (en) Heterocyclic compound
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
IL252560B (en) Heterocyclic derivatives and their uses
IL285105A (en) Heterocyclic compound
HK1243342A1 (zh) 化合物和方法
GB201608779D0 (en) Methods and compounds
GB201608776D0 (en) Methods and compounds
EP3197885A4 (en) Heterocyclic compounds and use thereof
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
PT3268356T (pt) Compostos heterocíclicos e métodos para a sua utilização
GB201416351D0 (en) Heterocyclic derivatives
IL258458B (en) Peroxyhemiacetal profragrant and proflavor compounds
AU2015903010A0 (en) Heterocyclic Compounds and Methods for their Use
AU2015902922A0 (en) Heterocyclic compounds and methods for their use
AU2015902886A0 (en) Heterocyclic Compounds And Methods For Their Use
AU2015902830A0 (en) Heterocyclic compounds and methods for their use
AU2015901751A0 (en) Heterocyclic Compounds And Methods For Their Use
AU2015900878A0 (en) Heterocyclic compounds and methods for their use
AU2015900077A0 (en) Heterocyclic compounds and methods for their use
GB201514770D0 (en) Compounds and their use